<p><h1>Enasidenib Drugs Market Size Furnishes Valuable Information Encompassing Market Share, Market Trends, and Projections Spanning from 2023 to 2030</h1></p><p><strong>Enasidenib Drugs Market Analysis and Latest Trends</strong></p>
<p><p>Enasidenib is an oral medication that belongs to the class of drugs known as isocitrate dehydrogenase-2 (IDH2) inhibitors. It is used for the treatment of relapsed or refractory acute myeloid leukemia (AML) that carries an IDH2 mutation. Enasidenib works by blocking the mutated IDH2 enzyme, which helps promote the differentiation of leukemia cells into normal blood cells.</p><p>The global Enasidenib drugs market is anticipated to experience significant growth during the forecast period. The market analysis suggests that the market is expected to grow at a CAGR of 7.9%. The increasing prevalence of acute myeloid leukemia, particularly in the elderly population, is one of the major factors driving the market growth. Additionally, the market is fueled by the rising demand for targeted therapies and advancements in precision medicine.</p><p>Several pharmaceutical companies are actively involved in the development and commercialization of Enasidenib drugs. These companies are investing in research and development activities to expand the therapeutic indications of Enasidenib and improve patient outcomes. Moreover, the market is witnessing collaborations among pharmaceutical manufacturers and academic institutions to accelerate drug discovery and development processes.</p><p>Furthermore, the market is expected to witness enhanced market penetration due to the increasing approvals and emerging pipelines of novel IDH2 inhibitors. It is anticipated that the market will witness key developments such as drug approvals, clinical trials, and collaborations, which will contribute to its growth.</p><p>In conclusion, the Enasidenib drugs market is projected to grow at a CAGR of 7.9% during the forecast period. The increasing prevalence of acute myeloid leukemia, advancements in precision medicine, and ongoing research and development activities are the key factors propelling the market growth. The market is expected to witness significant developments, including drug approvals and collaborations, which will further contribute to its expansion.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp; <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1358887">https://www.reliableresearchreports.com/enquiry/request-sample/1358887</a></strong></p>
<p>&nbsp;</p>
<p><strong>Enasidenib Drugs Major Market Players</strong></p>
<p><p>Enasidenib is a drug used for the treatment of acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. One of the key players in the Enasidenib drugs market is Celgene Corporation, a renowned biopharmaceutical company based in the United States. Celgene Corporation, a subsidiary of Bristol-Myers Squibb, focuses on the discovery, development, and commercialization of innovative therapies to treat various forms of cancer and immune-inflammatory diseases.</p><p>Celgene Corporation has a rich history of more than three decades in the field of biopharmaceuticals, with a primary focus on oncology and immunology. The company has a strong track record of developing innovative drugs and bringing them to market successfully. In 2017, Celgene received FDA approval for Enasidenib (marketed as Idhifa), which became the first targeted therapy specifically approved for AML patients with an IDH2 mutation who have relapsed or refractory disease.</p><p>The Enasidenib market has witnessed significant growth in recent years due to the high prevalence of AML and the effectiveness of targeted therapies. Currently, there are several players in the Enasidenib drugs market competing with Celgene Corporation. Key competitors include Agios Pharmaceuticals, Astellas Pharma, and Daiichi Sankyo.</p><p>Agios Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of medicines for the treatment of cancer and rare genetic diseases. The company has a pipeline of potential targeted therapies, including small molecules targeting IDH mutations. Astellas Pharma and Daiichi Sankyo are also actively involved in the development of targeted therapies for AML and other forms of cancer.</p><p>In terms of sales revenue, Celgene Corporation reported significant revenue from its hematology oncology portfolio, including Enasidenib. In the financial year 2019, Celgene reported total revenue of $17.03 billion. However, specific sales revenue figures for Enasidenib were not publicly disclosed.</p><p>Overall, Celgene Corporation, along with its competitors in the Enasidenib drugs market, plays a crucial role in advancing the treatment options for AML patients with an IDH2 mutation. The market for Enasidenib is expected to continue growing as more clinical research and development efforts focus on targeted therapies for AML and other types of cancer.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Enasidenib Drugs Manufacturers?</strong></p>
<p><p>The Enasidenib drugs market has experienced significant growth in recent years and is expected to continue its upward trajectory in the future. Enasidenib is an orally administered targeted therapy used for treating relapsed or refractory acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation. Factors driving the market growth include the increasing prevalence of AML, rising treatment-seeking population, and advancements in medical research. Moreover, the approval of enasidenib by regulatory authorities and extensive clinical trials have also contributed to market expansion. Future outlook therefore appears promising for the Enasidenib drugs market, with increasing demand and novel therapeutic developments anticipated.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report: <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1358887">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1358887</a></strong></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Enasidenib Drugs Market Analysis by types is segmented into:</strong></p>
<p><ul><li>50mg</li><li>100mg</li></ul></p>
<p><p>Enasidenib drugs are available in two market types, namely the 50mg and 100mg market. The 50mg market refers to the distribution and availability of Enasidenib drugs in a dosage strength of 50mg. This option provides a lower concentration of the drug and is suitable for patients who require a lower dosage. Conversely, the 100mg market represents the distribution and availability of Enasidenib drugs in a higher dosage strength of 100mg. This dosage is typically prescribed to patients requiring a higher concentration of the medication.</p></p>
<p><strong>Purchase this Report:&nbsp;<a href="https://www.reliableresearchreports.com/purchase/1358887">https://www.reliableresearchreports.com/purchase/1358887</a></strong></p>
<p>&nbsp;</p>
<p><strong>The Enasidenib Drugs Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Pharmacy</li></ul></p>
<p><p>Enasidenib is a drug used in the treatment of acute myeloid leukemia (AML) with specific genetic mutations. In the hospital market, enasidenib is typically prescribed by oncologists or hematologists and administered to patients as part of their inpatient treatment. In the pharmacy market, enasidenib is dispensed to patients upon a valid prescription and can be used for outpatient treatment. Both markets play a crucial role in providing access to enasidenib, ensuring that patients receive the medication they need for managing their AML.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Enasidenib Drugs Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The market for Enasidenib drugs is poised for significant growth across regions such as North America (NA), Asia Pacific (APAC), Europe, the United States (USA), and China. North America currently holds a substantial share in the market due to increased demand for innovative treatment options and the presence of major pharmaceutical companies. Similarly, Europe has witnessed steady growth owing to advancements in healthcare infrastructure and rising prevalence of cancer. However, it is anticipated that the Asia Pacific region, particularly China, will dominate the Enasidenib drugs market in the coming years with a notable market share percentage valuation, driven by a large patient pool and improving healthcare expenditure.</p></p>
<p><strong>Purchase this Report: <a href="https://www.reliableresearchreports.com/purchase/1358887">https://www.reliableresearchreports.com/purchase/1358887</a></strong></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;<a href="https://www.reliableresearchreports.com/enquiry/request-sample/1358887">https://www.reliableresearchreports.com/enquiry/request-sample/1358887</a></strong></p>
<p><strong></strong></p>
<p><p><a href="https://medium.com/@jensenklein/crystalline-ceramics-market-size-growth-forecast-2023-2030-2d63867a8afe">Crystalline Ceramics Market</a></p><p><a href="https://github.com/Chiragrp23/Market-Research-Report-List-1/blob/main/drugs-for-differentiated-thyroid-cancer-market.md">Drugs for Differentiated Thyroid Cancer Market</a></p><p><a href="https://github.com/Chiragrp24/Market-Research-Report-List-1/blob/main/outsourced-drug-discovery-market.md">Outsourced Drug Discovery Market</a></p><p><a href="https://medium.com/@edenkrajcik/biofuel-additives-market-size-growth-forecast-2023-2030-224751599f32">Biofuel Additives Market</a></p><p><a href="https://www.linkedin.com/pulse/cassette-player-market-size-share-global-analysis-report-umqye/">Cassette Player Market</a></p></p>